Future Oncology
Volume 19, 2023 - Issue 1
Open access
2,273
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma
Barry Paul1 Levine Cancer Institute,Department of Hematologic Oncology and Blood Disorders,Charlotte,NC 28204,USACorrespondence[email protected]
https://orcid.org/0000-0003-2702-8225
, https://orcid.org/0000-0003-2702-8225
Michaela Liedtke2 Stanford Cancer Institute,Stanford Comprehensive Cancer Center,Stanford,CA94305,USAhttps://orcid.org/0000-0001-8945-5850
, Jack Khouri3 Taussig Cancer Institute,Cleveland Clinic,Department of Hematology and Medical Oncology,Cleveland,OH 44195,USAhttps://orcid.org/0000-0002-2473-6528
, Robert Rifkin4 Rocky Mountain Cancer Centers,US Oncology Research,Denver,CO 80218,USAhttps://orcid.org/0000-0003-3141-1518
, Mitul D Gandhi5 Virginia Cancer Specialists,Gainesville,VA 20155,USAhttps://orcid.org/0000-0002-3263-2374
, Andrew Kin6 Barbara Ann Karmanos Cancer Institute,Wayne State University,Department of Oncology,Detroit,MI 48201,USA
, Moshe Y Levy7 Baylor University Medical Center,Department of Hematology and Medical Oncology,Dallas,TX 75246,USA
, Rebecca Silbermann8 Oregon Health & Science University,Division of Hematology/Medical Oncology,Portland,OR 97239,USAhttps://orcid.org/0000-0002-7571-1523
, Francesca Cottini9 The Ohio State University Comprehensive Cancer Center,Department of Internal Medicine,Columbus,OH 43210,USAhttps://orcid.org/0000-0001-8676-7840
, Douglas W Sborov10 Huntsman Cancer Institute,University of Utah,Department of Internal Medicine,Salt Lake City,UT 84112,USAhttps://orcid.org/0000-0003-4268-2698
, Irwindeep Sandhu11 Cross Cancer Institute,University of Alberta,Department of Oncology,Edmonton,Alberta,T6G 1Z2,Canadahttps://orcid.org/0000-0001-9407-6265
, Lyssa Villarreal12 Gilead Sciences, Inc,Foster City,CA 94404,USA
, Michael Murphy12 Gilead Sciences, Inc,Foster City,CA 94404,USAhttps://orcid.org/0000-0001-6529-6824
, Lin Gu12 Gilead Sciences, Inc,Foster City,CA 94404,USAhttps://orcid.org/0000-0003-4593-8572
, Ann Chen12 Gilead Sciences, Inc,Foster City,CA 94404,USA
, Nishanthan Rajakumaraswamy12 Gilead Sciences, Inc,Foster City,CA 94404,USAhttps://orcid.org/0000-0002-0226-0637
& Saad Z Usmani13 Memorial Sloan Kettering Cancer Center,New York City,NY 10065,USAhttps://orcid.org/0000-0002-5484-8731
show all
Pages 7-17
|
Received 30 Sep 2022, Accepted 22 Dec 2022, Published online: 13 Feb 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.